Less costly treatment with compact proton therapy

PROTON therapy solutions leader, Ion Beam Applications SA (IBA), said that the first cancer patient has been treated with IBA’s compact proton therapy solution, Proteus?ONE. The patient received Image Guided Intensity Modulated Proton Therapy (IMPT) treatment on 9 September 2014, three months ahead of schedule at the Willis-Knighton Cancer Center (WKCC) in Shreveport, Louisiana, USA.

Proteus?ONE is the only product in radiation therapy to be recognized by two leading design awards

Belgium-based IBA believes that the treatment of the first ever patient on the compact, more affordable system will accelerate the take-up of proton therapy in the US and beyond. The company received Marketing Authorization from the U.S. Food and Drug Administration (FDA) in July 2014 and CE mark for its Compact Gantry Beam Line in September 2014.

The first patient treatment occurred less than 14 months after arrival of the equipment at WKCC, faster than any competitive solution in the market and underscoring IBA’s ability to deliver proton therapy swiftly and reliably to its customers all over the world.

“This speed of delivery further bolsters our conviction that Proteus?ONE will be a significant driver of proton therapy adoption worldwide," said IBA chief executive officer Olivier Legrain.

Four other Proteus ONE systems have been sold  in France, Taiwan and two in Japan. and IBA anticipates that the international interest will continue to build momentum.